FrancophonIA/ELRC3.0 huggingface dataset:
English: Excipientwith known effect: each film coated tablet contains 183.13 mg lactose (as monohydrate).
Estonian: Teadaolevat toimet omavad abiained: iga õhukese polümeerikattega tablett sisaldab 183,13 mg laktoosi (monohüdraadina).
English: Each film-coated tablet contains 15 mg memantine hydrochloride equivalent to 12.46 mg memantine.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 15 mg memantiinvesinikkloriidi, mis vastab 12,46 mg memantiinile.
English: How to store Memantine Accord
Estonian: Kuidas Memantine Accord'i säilitada
English: The 15 mg film-coated tablets are orange to grey-orange, oblong, coated tablets debossedwith "MT" on one side and "15" on the other side.
Estonian: 15 mg õhukese polümeerikattega tabletid on oranžid või hallikas-oranžid piklikud kattega tabletid, mille ühele küljele on pressitud „MT“ ja teisele küljele „15“.
English: Each film-coated tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 10 mg memantiinvesinikkloriidi, mis vastab 8,31 mg memantiinile.
English: In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.
Estonian: Sellisel juhul peab arst regulaarselt jälgima teie neerutalitlust.
English: Do not pass it on to others.
Estonian: Ravim on välja kirjutatud ainult teile ja seda ei tohi anda kellelegi teisele.
English: The 10 mg film-coated tablets are white, oblong, coated and scored tablets, debossed with "MT" divided by the score on one side and "10" divided by the score on the other side.
Estonian: 10 mg õhukese polümeerikattega tabletid on valged, piklikud, kattega ja murdejoonega tabletid, mille ühel küljel on murdejoon ja pressitud tähis „MT“ ning teisel küljel murdejoon ja tähis „10“.
English: Memantine Accord 15 mg film-coated tablets are presented as orange to grey-orange, oblong, coated tablet, debossed with “MT” on one side and “15” on the other side.
Estonian: Memantine Accord'i 15 mg õhukese polümeerikattega tabletid on oranžid või hallikas-oranžid piklikud kattega tabletid, mille ühele küljele on pressitud „MT“ ja teisele küljele „15“.
English: Each film-coated tablet contains 5/10/15/20 mg of memantine hydrochloride equivalent to 4.15/8.31/12.46/16.62 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), and additional for Memantine Accord 15 mg and Memantine Accord 20 mg film-coated tablets iron oxide yellow and red (E 172), all in the tablet coating
Estonian: Tableti kest: hüpromelloos, polüsorbaat 80, makrogool 400, titaandioksiid (E 171) ning Memantine Accord'i 15 mg ja Memantine Accord'i 20 mg õhukese polümeerikattega tablettides veel kollane ja punane raudoksiid (E 172)
English: Alzheimer´s disease assessment scale (ADAS-cog) (p = 0.003) and CIBIC-plus (p = 0.004) at week 24 last observation carried forward (LOCF).
Estonian: tajutav muutus arsti intervjuu põhjal (CIBIC-Plus): p = 0,025; Alzheimer'i tõve ühisuuringigapäevategevused (ADCS-ADLsev): p = 0,003; raske häire kogum (SIB): p = 0,002).
English: Hypromellose
Estonian: Metabolism
English: NAME OF THE MEDICINAL PRODUCT Memantine Accord 20 mg film-coated tablets memantine hydrochloride
Estonian: RAVIMPREPARAADI NIMETUS Memantine Accord 20 mg õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: EU/1/13/880/009 28 fim-coated tablets EU/1/13/880/010 42 fim-coated tablets EU/1/13/880/011 56 fim-coated tablets EU/1/13/880/012 98 fim-coated tablets EU/1/13/880/015 14 fim-coated tablets
Estonian: EU/1/13/880/009 28 õhukese polümeerikattega tabletid EU/1/13/880/010 42 õhukese polümeerikattega tabletid EU/1/13/880/011 56 õhukese polümeerikattega tabletid EU/1/13/880/012 98 õhukese polümeerikattega tabletid EU/1/13/880/015 14 õhukese polümeerikattega tabletid
English: The patient should take one 10 mg film-coated tablet per day for 7 days.
Estonian: Patsient peab võtma ühe 10 mg õhukese polümeerikattega tableti (10 mg) ööpäevas 7 päeva.
English: The 20 mg film-coated tablets are pale red to grey-red, oblong, scored, coated tablets, debossed with "MT" divided by the score on one side and "20" divided by the score on the other side.
Estonian: 20 mg õhukese polümeerikattega tabletid on kahvatupunased või hallikas-punased piklikud murdejoonega, kattega tabletid, mille ühel küljel on murdejoon ja pressitud tähis„MT“ ning teisel küljel murdejoon ja tähis „20“.
English: Memantine Accord 20 mg film-coated tablets
Estonian: Memantine Accord 20 mg õhukese polümeerikattega tabletid.
English: White, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and "10" divided by the score on the other side.
Estonian: Valge, piklik, kaetud ja poolitusjoonega tablett, mille ühele küljele on sisse pressitud ,,MT“ ja poolitusjoon ning teisele küljele ,,10“ ja poolitusjoon.
English: NAME OF THE MEDICINAL PRODUCT Memantine Accord 10 mg film-coated tablets memantine hydrochloride
Estonian: RAVIMPREPARAADI NIMETUS Memantine Accord 10 mg õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: What Memantine Accord is and what it is used for 2.
Estonian: Mille kohta antakse ülevaade selles infolehes 1. Mis ravim on Memantine Accord ja milleks seda kasutatakse 2. Mida on vaja teada enne Memantine Accord'i kasutamist 3.
English: EU/1/13/880/020 14 x 1 film-coated tablets EU/1/13/880/021 28 x 1 film-coated tablets EU/1/13/880/022 56 x 1 film-coated tablets EU/1/13/880/023 98 x 1 film-coated tablets
Estonian: EU/1/13/880/020 14 x1 õhukese polümeerikattega tabletti EU/1/13/880/021 28 x1 õhukese polümeerikattega tabletti EU/1/13/880/022 56 x1 õhukese polümeerikattega tabletti EU/1/13/880/023 98 x1 õhukese polümeerikattega tabletti
English: Each film-coated tablet contains 20 mg memantine hydrochloride equivalent to 16.62 mg memantine.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 20 mg memantiinvesinikkloriidi, mis vastab 16,62 mg memantiinile.
English: If you have impaired kidney function, your doctor will decide upon a dose that suits your condition.
Estonian: Annustamine neerutalitluse häirega patsientidel Kui teil esineb neerutalitluse häire, määrab arst teile sobiva annus.
English: The patient should take one 15 mg film-coated tablet per day for 7 days.
Estonian: Patsient peab võtma ühe 15 mg õhukese polümeerikattega tableti ööpäevas (hallikas-oranžid) 7 päeva jooksul.
English: EU/1/13/880/016 14 x 1 film-coated tablets EU/1/13/880/017 28 x 1 film-coated tablets EU/1/13/880/018 56 x 1film-coated tablets EU/1/13/880/019 98 x 1film-coated tablets
Estonian: EU/1/13/880/016 14 x1 õhukese polümeerikattega tabletti EU/1/13/880/017 28 x1 õhukese polümeerikattega tabletti EU/1/13/880/018 56 x1 õhukese polümeerikattega tabletti EU/1/13/880/019 98 x1 õhukese polümeerikattega tabletti
English: Memantine Accord 10 mg film-coated tablets
Estonian: Memantine Accord 10 mg õhukese polümeerikattega tabletid.
English: 15 mg tablet week 4 and beyond 20 mg tablets once a day Maintenance dose
Estonian: 20 mg tablett üks kord päevas
English: Name and address of the manufacturers responsible for batch release
Estonian: Ravimipartii vabastamise eest vastutava(te) tootja(te) nimi ja aadress Delorbis Pharmaceuticals Ltd
English: Memantine Accord 20 mg film-coated tablets are presented as pale red to greyred, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and “20” divided by the score on the other side.
Estonian: Memantine Accord'i 20 mg õhukese polümeerikattega tabletid onkahvatupunased või hallikaspunased, piklikud, kattega ja poolitusjoonega, tabletid, mille ühel küljel on poolitusjoon ja märgistus „MT“ ning teisel küljel poolitusjoon ning märgistus „20“.
English: PC:
Estonian: SN:
English: Pale red to grey-red, oblong, scored, coated tablet, debossed with “MT” divided by the score on one side and "20" divided by the score on the other side.
Estonian: Kahvatupunased või hallikas-punased, piklikud, murdejoonega kattega tabletid, mille ühel küljel on murdejoon ja pressitud tähis „MT“ ning teisel küljel murdejoon ja tähis „20“.
English: 20days, more than 99 % being excreted renally.
Estonian: 99% eritus neerude kaudu.
English: Date of first authorisation: 04 December 2013
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamine: 04-12-2013
English: Memantine Accord 10 mg film-coated tablets memantine hydrochloride
Estonian: Memantine Accord 10 mg õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: Memantine Accord film-coated tablets are presented as pale red to greyred, oblong, coated and scored tablet, debossed with "MT" divided by the score on one side and “20” divided by the score on the other side.
Estonian: Memantine Accord õhukese polümeerikattega tabletid on kahvatupunased või hallikas-punased, piklikud, poolitusjoonega, kattega tabletid, mille ühel küljel on poolitusjoon ja märgistus „MT“ ning teisel küljel poolitusjoon ning märgistus „20“.
English: Treatment initiation pack
Estonian: Ravi alustamise karp.
English: Week 1 Week 2 Week 3 Week 4
Estonian: 1. nädal (1….7.
English: Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), iron oxide red (E 172), iron oxide yellow (E 172) all in the tablet coating
Estonian: Tableti kest: hüpromelloos, polüsorbaat 80,makrogool 400, titaandioksiid (E 171), punane raudoksiid (E 172), kollane raudoksiid (E 172).
English: Memantine Accord film-coated tablets are presented as white, oblong, coated and scored tablet,debossed with "MT" divided by the score on one side and “10” divided by the score on the other side.
Estonian: Memantine Accord õhukese polümeerikattega tabletid on valged, piklikud, kattega ja poolitusjoonega tabletid, mille ühel küljel on poolitusjoon ja märgistus „MT“ ning teisel küljel poolitusjoon ning märgistus „10“.
English: Memantine Accord 20 mg film-coated tablets memantine hydrochloride
Estonian: Memantine Accord 20 mg õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: Uncommon Confusion Uncommon Hallucinations1
Estonian: Hallutsinatsioonid1
English: Film-coated tablet.
Estonian: Õhukese polümeerkattega tablett.
English: NAME OF THE MEDICINAL PRODUCT Memantine Accord 5 mg film-coated tablets
Estonian: Memantine Accord 5 mg õhukese polümeerikattega tabletid.
English: Headache
Estonian: Südamehäired
English: The full EPAR for Docetaxel Kabi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Docetaxel Kabi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Kabi on 22 May 2012.
Estonian: Euroopa Komisjon andis Docetaxel Kabi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 22. mail 2012.
English: Docetaxel Kabi is given as a one-hour infusion every three weeks.
Estonian: Ravimit Docetaxel Kabi manustatakse üks tund kestva infusioonina iga kolme nädala tagant.
English: • non-small-cell lung cancer.
Estonian: • Mitteväikerakk-kopsuvähk.
English: Docetaxel Kabi docetaxel
Estonian: Docetaxel Kabi dotsetakseel
English: Therefore, the CHMP's view was that, as for Taxotere, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Taxotere korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: This is a summary of the European public assessment report (EPAR) for Docetaxel Kabi.
Estonian: See on Docetaxel Kabi Euroopa avaliku hindamisaruande kokkuvõte.
English: It is available as a concentrate to be made up into a solution for infusion (drip into a vein).
Estonian: Seda turustatakse kontsentraadina, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: It can also be used with other anticancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated;
Estonian: Ravimit tohib kasutada ka koos teiste vähiravimitega (doksorubitsiin, tsüklofosfamiid, trastusumaab või kapetsitabiin) patsientidel, kes ei ole veel vähiravi saanud, või pärast muude raviskeemide ebaõnnestumist, olenevalt ravitava rinnavähi vormist ja staadiumist.
English: Docetaxel Kabi is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Estonian: Ravimit Docetaxel Kabi kasutatakse ainult juhul, kui neutrofiilide (valgeliblede liik) sisaldus veres on normaalne (vähemalt 1500 rakku/mm3).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Docetaxel Kabi.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The company provided data from published literature on docetaxel.
Estonian: Ettevõte esitas dotsetakseeli kohta avaldatud kirjandusest pärinevad andmed.
English: For more information about treatment with Docetaxel Kabi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Docetaxel Kabi toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated.
Estonian: Annus, ravi kestus ja ravimi kasutamine koos teiste ravimitega oleneb ravitava vähi vormist.
English: The CHMP concluded that, in accordance with EU requirements, Docetaxel Kabi has been shown to be comparable to Taxotere.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Docetaxel Kabi võrreldavus ravimiga Taxotere.
English: No additional studies were needed as Docetaxel Kabi is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.
Estonian: Lisauuringuid ei olnud vaja, sest Docetaxel Kabi on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Taxotere.
English: Because Docetaxel Kabi is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Docetaxel Kabi on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Committee recommended that Docetaxel Kabi be given marketing authorisation.
Estonian: Komitee soovitas anda Docetaxel Kabi müügiloa.
English: Docetaxel also affects non-cancer cells such as blood cells, which can cause side effects.
Estonian: Dotsetakseel mõjub peale vähirakkude ka muudele rakkudele, näiteks vererakkudele, ja see võib põhjustada kõrvalnähte.
English: For full details, see the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: This means that Docetaxel Kabi is similar to a ‘reference medicine' already authorised in the European Union (EU) called Taxotere.
Estonian: See tähendab, et Docetaxel Kabi on sarnane võrdlusravimiga Taxotere, millel juba on Euroopa Liidus müügiluba.
English: The company also showed that the Docetaxel Kabi solution for infusion has comparable quality to that of Taxotere.
Estonian: Ettevõte esitas ka andmed, et Docetaxel Kabi infusioonilahuse kvaliteet on võrreldav Taxotere kvaliteediga.
English: • prostate cancer, when the cancer does not respond to hormonal treatment.
Estonian: • Eesnäärmevähk, mis ei allu hormoonravile.
English: Other information about Docetaxel Kabi
Estonian: Muu teave Docetaxel Kabi kohta
English: Docetaxel Kabi is used with prednisone or prednisolone (anti-inflammatory medicines);
Estonian: Ravimit Docetaxel Kabi kasutatakse koos prednisooni või prednisolooniga (põletikuravimid).
English: Docetaxel Kabi is used to treat the following types of cancer:
Estonian: Ravimit Docetaxel Kabi kasutatakse järgmiste vähivormide ravimiseks:
English: Docetaxel Kabi can be used on its own after other treatments have failed.
Estonian: Ravimit Docetaxel Kabi tohib kasutada ainsa ravimina pärast muude raviskeemide ebaõnnestumist.
English: Docetaxel Kabi is a ‘generic medicine'.
Estonian: Docetaxel Kabi on geneeriline ravim.
English: Docetaxel Kabi is used with cisplatin and 5-fluorouracil.
Estonian: Ravimit Docetaxel Kabi kasutatakse koos tsisplatiini või 5-fluorouratsiiliga.
English: Docetaxel Kabi is a medicine that contains the active substance docetaxel.
Estonian: Docetaxel Kabi on ravim, mis sisaldab toimeainena dotsetakseeli.
English: It can also be used with cisplatin (another anticancer medicine) in patients who have not yet received any treatment for their cancer;
Estonian: Seda tohib kasutada ka koos tsisplatiiniga (samuti vähiravim) patsientidel, kes ei ole veel vähiravi saanud.
English: What is Docetaxel Kabi?
Estonian: Mis on Docetaxel Kabi?
English: Why has Docetaxel Kabi been approved?
Estonian: Miks Docetaxel Kabi heaks kiideti?
English: Docetaxel Kabi should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Estonian: Ravi Docetaxel Kabiga peab toimuma keemiaravile (vähi ravimravi) spetsialiseerunud osakonnas keemiaravipädevusega arsti järelevalve all.
English: Docetaxel Kabi is used with cisplatin and 5-fluorouracil (other anticancer medicines);
Estonian: Ravimit Docetaxel Kabi kasutatakse koos tsisplatiini või 5-fluorouratsiiliga (samuti vähiravimid).
English: The active substance in Docetaxel Kabi, docetaxel, belongs to the group of anticancer medicines known as the taxanes.
Estonian: Docetaxel Kabi toimeaine dotsetakseel kuulub vähiravimite taksaanide rühma.
English: An anti-inflammatory medicine such as dexamethasone should also be given to the patient, starting on the day before the Docetaxel Kabi infusion.
Estonian: Alates Docetaxel Kabi infusioonile eelnevast päevast tuleb anda patsiendile ka põletikuravimit deksametasooni.
English: How has Docetaxel Kabi been studied?
Estonian: Kuidas ravimit Docetaxel Kabi uuriti?
English: What are the benefits and risks of Docetaxel Kabi?
Estonian: Milles seisneb Docetaxel Kabi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How does Docetaxel Kabi work?
Estonian: Kuidas Docetaxel Kabi toimib?
English: How is Docetaxel Kabi used?
Estonian: Kuidas ravimit Docetaxel Kabi kasutatakse?
English: What is Docetaxel Kabi used for?
Estonian: Milleks ravimit Docetaxel Kabi kasutatakse?
English: Protection prevents mortality and reduces infection and disease.
Estonian: Kaitse ennetab suremust ning vähendab infektsiooni ja haigestumist.
English: The purpose of these studies was to establish how long it took for pigs to be fully protected and the length of time protection lasts against CSFV.
Estonian: Uuringute eesmärk oli leida, kui kiiresti tekib sigadel täielik kaitse ja kui kaua kestab kaitse CSFV vastu.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Suvaxyn CSF Marker on 10/02/2015.
Estonian: Euroopa Komisjon andis Suvaxyn CSF Markeri müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 10/02/2015.
English: This summary was last updated in December 2014.
Estonian: Kokkuvõtte viimane uuendus: 12-2014.
English: Classical swine fever vaccine (live recombinant)
Estonian: Sigade klassikalise katku vaktsiin (elus rekombinantne)
English: The laboratory studies showed that the vaccine had its full effect against CSFV by two weeks.
Estonian: Laboriuuringud tõendasid, et vaktsiin avaldas CSFV vastu täielikku mõju teiseks nädalaks.
English: As CSF is a notifiable disease, it is not possible to conduct standard field studies.
Estonian: Et CSF-st teatamine on kohustuslik, ei ole võimalik teha tavapäraseid väliuuringuid.
English: The effectiveness of Suvaxyn CSF Marker was further investigated in a small scale study with 30 eight-week-old piglets.
Estonian: Suvaxyn CSF Markeri efektiivsust uuriti täiendavalt väikesemahulises uuringus, kus osales 30 kaheksa nädala vanust põrsast.
English: This disease causes fever, skin lesions, convulsions and often leads to death of the animals.
Estonian: Haigus tekitab palavikku, nahakahjustusi ja konvulsioone ning lõpeb sageli looma surmaga.
English: The main measure of effectiveness was development of antibodies against E2 protein 14 days after vaccination.
Estonian: Efektiivsuse põhinäitaja oli antikehade teke valgu E2 vastu 14 päeva pärast vaktsineerimist.
English: Protection lasted at least six months after vaccination.
Estonian: Kaitse püsis pärast vaktsineerimist vähemalt 6 kuud.
English: Protection starts two weeks after vaccination and lasts for at least six months.
Estonian: Kaitse haiguse vastu tekib 2 nädalat pärast vaktsineerimist ja püsib vähemalt 6 kuud.
English: This will help to protect against the disease.
Estonian: See aitab sigu haiguse eest kaitsta.
English: The CVMP concluded that the benefits of Suvaxyn CSF Marker exceed the risks for the approved indication and recommended that Suvaxyn CSF Marker be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustusel on Suvaxyn CSF Markeri kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda Suvaxyn CSF Markeri müügiloa.
English: The withdrawal period for Suvaxyn CSF Marker for pigs is zero days.
Estonian: Suvaxyn CSF Markeri keeluaeg sigadel on 0 päeva.
English: The vaccine has potential marker properties which may allow detection of pigs infected with field CSFV as distinct from Suvaxyn CSF Marker vaccinated pigs, in accordance with the DIVA principle (differentiation of infection from vaccination).
Estonian: Vaktsiinil on potentsiaalsed markeromadused, mis võivad aidata eristada CSFV-ga nakatunud sigu Suvaxyn CSF Markeriga vaktsineeritud sigadest DIVA-põhimõtte kohaselt (infektsiooni ja vaktsineerimise eristamine).
English: The vaccine is available as a lyophilisate (freeze dried powder) and solvent for injection.
Estonian: Vaktsiini turustatakse süstesuspensiooni lüofilisaadi (külmkuivatatud pulbri) ja lahustina.
English: Suvaxyn CSF Marker is a vaccine containing bovine viral diarrhoea virus, which can infect pigs but does not normally cause disease in them.
Estonian: Suvaxyn CSF Marker on vaktsiin, mis sisaldab veiste viirusdiarröa viirust, mis võib sigu nakatada, kuid ei põhjusta neil tavaliselt haigust.
English: The vaccine virus in Suvaxyn CSF Marker has been modified so that it will produce the E2 protein, which is part of the outer coat of the closely related virus CSFV, which it provides protection against.
Estonian: Vaktsiinis Suvaxyn CSF Marker sisalduvat viirust on muudetud, et see tekitaks valku E2, mis sisaldub lähedalt seotud viiruse CSFV välisümbrises ja kaitseb CSFV eest.
English: In the future, if the animals are exposed to CSFV, their immune system will be triggered by the virus and be able to respond more quickly.
Estonian: Kui loomad puutuvad hiljem CSFV-ga uuesti kokku, toimib viirus immuunsüsteemile ja antikehad tekivad kiiremini.
English: Suvaxyn CSF Marker should not be used to vaccinate sows.
Estonian: Suvaxyn CSF Markeriga ei tohi vaktsineerida emiseid.
English: Twenty piglets were given Suvaxyn CSF Marker and 10 piglets were given a placebo (dummy) injection.
Estonian: 20 põrsale süstiti Suvaxyn CSF Markerit ja 10 põrsale platseebot (näiv ravim).